Title |
Methotrexate for maintenance of remission in Crohn's disease
|
---|---|
Published in |
Cochrane database of systematic reviews, August 2014
|
DOI | 10.1002/14651858.cd006884.pub3 |
Pubmed ID | |
Authors |
Vishal Patel, Yongjun Wang, John K MacDonald, John WD McDonald, Nilesh Chande |
Abstract |
Safe and effective long-term treatments that reduce the need for corticosteroids are needed for Crohn's disease. Although purine antimetabolites are moderately effective for maintenance of remission patients often relapse despite treatment with these agents. Methotrexate may provide a safe and effective alternative to more expensive maintenance treatment with TNF-α antagonists. This review is an update of a previously published Cochrane review. |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | 25% |
France | 1 | 25% |
United States | 1 | 25% |
Unknown | 1 | 25% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 3 | 75% |
Practitioners (doctors, other healthcare professionals) | 1 | 25% |
Mendeley readers
The data shown below were compiled from readership statistics for 263 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 3 | 1% |
Chile | 1 | <1% |
Colombia | 1 | <1% |
Italy | 1 | <1% |
United States | 1 | <1% |
Unknown | 256 | 97% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 27 | 10% |
Student > Master | 26 | 10% |
Student > Bachelor | 26 | 10% |
Student > Ph. D. Student | 21 | 8% |
Other | 21 | 8% |
Other | 57 | 22% |
Unknown | 85 | 32% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 107 | 41% |
Nursing and Health Professions | 13 | 5% |
Pharmacology, Toxicology and Pharmaceutical Science | 9 | 3% |
Biochemistry, Genetics and Molecular Biology | 7 | 3% |
Social Sciences | 6 | 2% |
Other | 26 | 10% |
Unknown | 95 | 36% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 June 2019.
All research outputs
#6,583,609
of 25,806,763 outputs
Outputs from Cochrane database of systematic reviews
#8,186
of 13,140 outputs
Outputs of similar age
#58,850
of 248,083 outputs
Outputs of similar age from Cochrane database of systematic reviews
#151
of 229 outputs
Altmetric has tracked 25,806,763 research outputs across all sources so far. This one has received more attention than most of these and is in the 74th percentile.
So far Altmetric has tracked 13,140 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 35.9. This one is in the 37th percentile – i.e., 37% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 248,083 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 76% of its contemporaries.
We're also able to compare this research output to 229 others from the same source and published within six weeks on either side of this one. This one is in the 34th percentile – i.e., 34% of its contemporaries scored the same or lower than it.